| Li, Yan |
NCT04035824: Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study |
|
|
| Completed | 4 | 605 | RoW | Gastrodia and Uncaria granule, Placebo of Gastrodia and Uncaria granule | Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Hypertension | 04/24 | 04/24 | | |
NCT05089448: Morning Versus Bedtime Dosing of Antihypertensive Medication |
|
|
| Recruiting | 4 | 300 | RoW | Alisartan, Amlodipine besylate | Yan Li | Hypertension, Blood Pressure, Drug Use | 06/26 | 09/26 | | |
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule |
|
|
| Recruiting | 4 | 480 | RoW | Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Functional Dyspepsia, Postprandial Distress Syndrome | 12/23 | 12/23 | | |
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease |
|
|
| Active, not recruiting | 3 | 3208 | RoW | IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE | Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University | Kawasaki Disease | 12/24 | 12/25 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
NCT04405154: A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer |
|
|
| Not yet recruiting | 2 | 32 | NA | Camrelizumab, SHR-1210, Cisplatin, Platinol, IMRT or VMAT | West China Hospital | Head and Neck Neoplasms | 05/23 | 05/25 | | |
NCT05299697: A Study of TG103 Injection in Overweight or Obesity |
|
|
| Recruiting | 2 | 195 | RoW | TG103 15 mg, TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 06/23 | 09/23 | | |
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV |
|
|
| Recruiting | 2 | 60 | RoW | Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo | Vigonvita Life Sciences | Respiratory Syncytial Virus Infection | 01/25 | 01/25 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Novartis Pharmaceuticals | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05056389: Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) |
|
|
| Recruiting | 1 | 20 | Europe | Oxaliplatin, Intraperitoneal catheter | Oslo University Hospital | Peritoneal Metastases, Colo-rectal Cancer | 03/23 | 06/23 | | |
| Recruiting | 1 | 76 | RoW | HS-10380, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia | 06/23 | 07/23 | | |
NCT06594315: Assessing Brain Metabolism Using MRS With Deuterated Glucose |
|
|
| Active, not recruiting | N/A | 80 | US | Deuterated Glucose, Hydrogen gas (H2) glucose, [6,6'-2H2] glucose, Magnetic Resonance Imaging (MRI), MRI, Blood Sample, MR spectroscopy (MRS), MRS | University of California, San Francisco | Glioma | 07/27 | 07/27 | | |
NCT06610604: Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules |
|
|
| Recruiting | N/A | 500 | RoW | thermal ablation, thyroidectomy | Ming-an Yu | Thyroid Nodule | 06/27 | 12/27 | | |
NCT05258461: An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy |
|
|
| Not yet recruiting | N/A | 108 | NA | use of a smartphone app for adverse event management, conventional adverse event management | Peking Union Medical College Hospital | Breast Cancer | 10/22 | 12/22 | | |
NCT03547856: A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients" |
|
|
| Recruiting | N/A | 10000 | RoW | | Yan Li | Hypertension, Blood Pressure, Cardiovascular Diseases | 09/26 | 12/26 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
| Recruiting | N/A | 4500 | RoW | | Shanghai Institute of Hypertension | Nocturnal Hypertension | 09/26 | 12/26 | | |
PROMISE, NCT04135911: A Prospective Study on The"Management of Hypertension in Young and Middle-aged Subjects in Enterprises Setting" |
|
|
| Suspended | N/A | 2000 | RoW | | Yan Li | Hypertension, Blood Pressure | 03/26 | 03/26 | | |
NCT05535400: Effects of Physical-Psychological Integrative Intervention on SCI Patient: a Pilot Randomized Controlled Trial |
|
|
| Completed | N/A | 72 | RoW | Physical-Psychological Integrative Intervention, Brief online didactic education | The Hong Kong Polytechnic University | Spinal Cord Injuries, Physical Inactivity, Depression, Chronic Pain | 12/22 | 07/23 | | |
| Recruiting | N/A | 60 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Fuchs Dystrophy, Pseudophakic Bullous Keratopathy | 06/26 | 06/26 | | |
NCT05558657: Effect of Acupressure on Constipation in Community-dwelling Spinal Cord Injury Patients: a Randomized Controlled Trial |
|
|
| Completed | N/A | 80 | RoW | Home-based, acupressure combined with nursing education, Home-based, manual light touch of the abdomen combined with nursing education | The Hong Kong Polytechnic University | Spinal Cord Injuries, Traditional Chinese Medicine | 09/24 | 09/24 | | |
NCT05531058: The Impact of a Web-based Psychoeducation Programme With a Motivational AI Chatbot on Covid-19 Vaccine Hesitancy |
|
|
| Completed | N/A | 168 | RoW | AI-driven Vaccine Communicator, Self-learning of COVID-19 vaccine knowledge | The Hong Kong Polytechnic University | Vaccine Hesitancy, COVID-19 | 06/24 | 06/24 | | |
NCT01243931: Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy |
|
|
| Recruiting | N/A | 80 | US | OCT-guided laser phototherapeutic keratectomy, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789 | Oregon Health and Science University, National Eye Institute (NEI) | Corneal Opacity | 12/26 | 12/26 | | |
NCT02109471: Observational Study of Corneal Opacities in Adults |
|
|
| Recruiting | N/A | 150 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Corneal Opacities (Scar and Stromal Dystrophy) | 12/25 | 12/25 | | |
| Recruiting | N/A | 75 | US | | Oregon Health and Science University | Uveitis | 12/25 | 12/25 | | |
NCT06306378: The Relationship Between Social Memory Disorders and Sleep Spindles in Children With Autism Spectrum Disorder |
|
|
| Recruiting | N/A | 60 | RoW | social memory levels and spindle levels | First Affiliated Hospital Xi'an Jiaotong University, Xi'an TCM Hospital of Encephalopathy | Autism Spectrum Disorder | 03/24 | 04/24 | | |
| Recruiting | N/A | 445 | US | Optical Coherence Tomography | Oregon Health and Science University | Keratoconus, Corneal Opacity, Corneal Dystrophy | 04/25 | 04/26 | | |
| Active, not recruiting | N/A | 60 | US | SKY Breath Intervention | University of California, San Francisco | Depression, Anxiety Disorders | 04/25 | 12/25 | | |
OCT IOL, NCT00532051: Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography |
|
|
| Recruiting | N/A | 690 | US | OCT measurements, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789 | Oregon Health and Science University, National Eye Institute (NEI) | Cataract | 07/26 | 07/26 | | |
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA |
|
|
| Recruiting | N/A | 492 | RoW | | LI YAN | T2DM | 12/25 | 07/26 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder |
|
|
| Not yet recruiting | N/A | 42 | RoW | abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy | First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital | Autism Spectrum Disorder, Autism in Children | 01/26 | 01/26 | | |
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China |
|
|
| Recruiting | N/A | 300 | RoW | Follow up | Fujian Maternity and Child Health Hospital | Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions | 12/25 | 05/26 | | |
| Recruiting | N/A | 300 | RoW | Diagnostic biomarker | Shixuan Wang | Uterine Sarcoma | 11/25 | 11/25 | | |
| Recruiting | N/A | 258 | US | | Oregon Health and Science University, National Eye Institute (NEI) | Keratoconus, Irregular; Contour of Cornea | 12/25 | 12/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Recruiting | N/A | 287 | Europe | Surgical treatment, Non-surgical treatment | Kolding Sygehus, Copenhagen University Hospital, Hvidovre, Zealand University Hospital, Oslo University Hospital, Helse Stavanger HF, Sahlgrenska University Hospital, Sweden, Uppsala University Hospital, Odense University Hospital, Hospital of Southern Jutland, Slagelse Hospital, Aalborg University Hospital, University Hospital, Umeå, Nordsjaellands Hospital, Holbaek Sygehus, Aarhus University Hospital, Copenhagen University Hospital, Herlev-Gentofte, University Hospital Bispebjerg and Frederiksberg, Viborg Regional Hospital, Karolinska University Hospital, Danderyd Hospital, Tampere University Hospital, Helsinki University Central Hospital | Fracture Humerus of Shaft | 12/25 | 07/31 | | |
NCT05858944: Home Blood Pressure Intervention in the Community Trial |
|
|
| Recruiting | N/A | 10000 | RoW | Intensive Home BP control, Home BP<125/75 mmHg, Standard Home BP control, Home BP<135/85 mmHg | Shanghai Institute of Hypertension | Home Blood Pressure | 12/29 | 06/30 | | |
| Recruiting | N/A | 450 | RoW | Healthy control specimen collection, Non-Borrmann IV patient specimen collection, Borrmann IV patient specimen collection | First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The Second Hospital of Shandong University, The General Hospital of Fushun Mining Bureau, The fourth People's Hospital of Changzhou, The First People's Hospital of Jingzhou | Stomach Neoplasms, Gut Microbiota, Metabolomics | 01/24 | 12/25 | | |
| Recruiting | N/A | 500 | RoW | YISAIPU® ( An etanercept biosimilar), a recombinant tumor necrosis factor receptor-Fc fusion protein, rhTNFR:Fc, csDMARDs | The First Affiliated Hospital of Xiamen University | Rheumatoid Arthritis | 06/25 | 12/25 | | |
| ZHANG, Litao |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06587685: A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis |
|
|
| Recruiting | 3 | 472 | RoW | PG-011Gel, PG-011Gel 3%, Vehicle, placebo | Prime Gene Therapeutics Co., Ltd. | Atopic Dermatitis | 12/24 | 01/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 2/3 | 645 | RoW | SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo | Reistone Biopharma Company Limited | Atopic Dermatitis | 09/23 | 07/24 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 199 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 10/25 | 01/26 | | |
NCT06058546: Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis |
|
|
| Recruiting | 2 | 180 | RoW | Jiuweihuaban Pill placebo, Placebo group, low dose Jiuweihuaban Pill, Low dose group, high dose Jiuweihuaban Pill, High dose group | Tasly Pharmaceutical Group Co., Ltd | Plaque Psoriasis | 10/25 | 10/25 | | |
| Wu, Lijun |
SMART, NCT06722586: Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia |
|
|
| Recruiting | 3 | 84 | RoW | Sirolimus, Rapamycin, mTOR inhibitor, Placebo | Peking University First Hospital, North China Pharmaceutical Co.,Ltd | Antiphospholipid (aPL)-positive, Thrombocytopaenia | 12/27 | 12/27 | | |
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Active Ankylosing Spondylitis | 11/22 | 01/23 | | |
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Non-radiographic Axial Spondyloarthritis | 04/23 | 06/23 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
| Recruiting | N/A | 116 | RoW | Leflunomide 10mg Tab, Prednisone Acetate, Placebos | Jiang lindi | Takayasu Arteritis | 12/22 | 12/22 | | |
| Kang, Xiaojing |
NCT03642535: Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention |
|
|
| Recruiting | 4 | 300 | RoW | ALA, Aminolevulinic Acid | Shanghai Dermatology Hospital, Huadong Hospital, Peking University First Hospital, The First Affiliated Hospital of Kunming Medical College, General Hospital of Ningxia Medical University, Chinese Academy of Medical Sciences | Actinic Keratoses | 06/25 | 06/25 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
| Lijun, Wu |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
